MISC

2006年3月

Effects of conditions for preparing nanoparticles composed of aminoethylcarbamoyl-beta-cyclodextrin and ethylene glycol diglycidyl ether on trap efficiency of a guest molecule

INTERNATIONAL JOURNAL OF PHARMACEUTICS
  • M Eguchi
  • ,
  • YZ Du
  • ,
  • Y Ogawa
  • ,
  • T Okada
  • ,
  • N Yumoto
  • ,
  • M Kodaka

311
1-2
開始ページ
215
終了ページ
222
記述言語
英語
掲載種別
DOI
10.1016/j.ijpharm.2005.12.015
出版者・発行元
ELSEVIER SCIENCE BV

Nanoparticles comprising copolymers of aminoetllylcarbamoyl-beta-cyclodextrin (AEC-beta-CD) and ethylene glycol diglycidyl ether (EGDGE) are prepared by an interfacial polyaddition reaction in a miniemulsion system. Polymers are formed in a W/O emulsion containing 0.25-10.0% (w/w) water and 5.0% (w/w) surfactant (MO-3S, tetraglycerin monoester, HLB 8.8), where simple particles are predominantly obtained when the water content is 1.0% and 5.0%. Notably, nano-size small particles (diameter: 0.3 mu m) are formed under the condition of 5.0% water and 5.0% surfactant, which have the highest beta-CD contents (75.5 wt.%) and the most positive xi-potential (53.6 mV). The xi-potential measurement indicates that the obtained particles have positive charge due to protonation of their amino groups below around pH 10. Actually, uptake of 8-anilino-1-naphthalenesulfonic acid (ANS) bearing negative charge (SO3-) and moderate hydrophobicity depends on the magnitude of xi-potential of the particles; viz., the particles with xi-potential of 53.6 mV show the highest efficiency of uptake. The diameter and the P-CD contents are closely related with the water/surfactant ratio, and the xi-potentials are dependent on both the diameter and the R-CD contents. Inclusion of ANS into the CD cavity of EGDGE/AEC-beta-CD particles can be controlled by electrostatic interaction between ANS (negatively charged) and the particle (positively charged). Namely, synergistic effect of cavity-inclusion and electrostatic interaction can dominate the uptake of guest molecules by the particles. (c) 2005 Elsevier B.V. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.ijpharm.2005.12.015
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000236526600029&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.ijpharm.2005.12.015
  • ISSN : 0378-5173
  • Web of Science ID : WOS:000236526600029

エクスポート
BibTeX RIS